Chemoprophylaxis and intermittent treatment for preventing malaria in children

M M Meremikwu1, A A A Omari, P Garner

  • 1University of Calabar, Department of Paediatrics, Calabar, Cross River State, Nigeria, PMB 1115. mmeremiku@yahoo.co.uk

Insights

Regular antimalarial drugs significantly reduce clinical malaria and severe anemia in young children. However, evidence is insufficient to determine their impact on overall mortality in endemic areas.

Area of Science:

  • Public Health
  • Infectious Diseases
  • Pediatrics

Background:

  • Malaria causes recurrent illness in children in endemic regions.
  • Intermittent antimalarial treatment is being considered for preschool children.

Purpose of the Study:

  • To evaluate the effectiveness of chemoprophylaxis and intermittent antimalarial drug treatment in preventing malaria among young children in malaria-endemic areas.

Main Methods:

  • Systematic review and meta-analysis of randomized and quasi-randomized controlled trials.
  • Searched multiple databases including Cochrane, MEDLINE, EMBASE, and LILACS up to April 2005.
  • Included trials comparing antimalarial drugs at regular intervals with placebo or no treatment in children aged 1 month to 6 years.

Main Results:

  • Nineteen trials involving 14,393 children were analyzed.
  • Antimalarial prophylaxis/intermittent treatment reduced clinical malaria episodes (RR 0.52, 95% CI 0.35-0.77) and severe anemia (RR 0.54, 95% CI 0.42-0.68).
  • No significant difference in all-cause mortality was detected (RR 0.82, 95% CI 0.65-1.04), though a potentially important difference cannot be excluded. No serious adverse events were reported.

Conclusions:

  • Antimalarial prophylaxis and intermittent treatment effectively decrease clinical malaria and severe anemia in preschool-aged children.
  • Current evidence is insufficient to conclude on the impact of these treatments on mortality.
  • Further research with larger sample sizes is needed to ascertain the effect on mortality.
Abstract

Related Concept Videos

Malaria01:29

Malaria

Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Smallpox01:24

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.